Pediatric Atopic Dermatitis Treatment Selection: Biologics vs Nonsteroidal Topical Therapies
ByBrian Keegan, MD, PhD, FAAD ,Alexa Hetzel, MS, PA-C ,Vikash D. Oza, MD ,Amy Spizuoco, DO, FAOCD Experts discuss the recent FDA approval of topical JAK inhibitors for children 2 years or older as a promising advancement in pediatric atopic dermatitis treatment, highlighting their efficacy, their safety, and the practical challenges of integrating these options into individualized care plans while emphasizing the importance of patient education, access, and ongoing monitoring.